{"nctId":"NCT01684878","briefTitle":"Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)","startDateStruct":{"date":"2012-10-22","type":"ACTUAL"},"conditions":["Ovarian Cancer"],"count":208,"armGroups":[{"label":"Part 1: Pertuzumab + Topotecan","type":"EXPERIMENTAL","interventionNames":["Drug: Paclitaxel (Chemotherapy)","Drug: Pertuzumab","Drug: Topotecan (Chemotherapy)"]},{"label":"Part 1: Pertuzumab + Paclitaxel","type":"EXPERIMENTAL","interventionNames":["Drug: Paclitaxel (Chemotherapy)","Drug: Pertuzumab","Drug: Placebo"]},{"label":"Part 2: Pertuzumab+Chemotherapy","type":"EXPERIMENTAL","interventionNames":["Drug: Gemcitabine (Chemotherapy)","Drug: Paclitaxel (Chemotherapy)","Drug: Pertuzumab","Drug: Topotecan (Chemotherapy)"]},{"label":"Part 2: Placebo+Chemotherapy","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Gemcitabine (Chemotherapy)","Drug: Paclitaxel (Chemotherapy)","Drug: Placebo","Drug: Topotecan (Chemotherapy)"]}],"interventions":[{"name":"Gemcitabine (Chemotherapy)","otherNames":[]},{"name":"Paclitaxel (Chemotherapy)","otherNames":[]},{"name":"Pertuzumab","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Topotecan (Chemotherapy)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed epithelial ovarian, primary peritoneal, and/or fallopian tube cancer that is platinum-resistant or refractory\n* Low Human epidermal growth factor receptor (HER) 3 messenger ribonucleic acid (mRNA) expression\n* At least one measurable and/or non-measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version (V) 1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2\n* Left ventricular ejection fraction (LVEF) greater than or equal to (\\>/=) 50 percent (%)\n* Negative serum pregnancy test in women of childbearing potential\n* Women of childbearing potential must agree to use effective contraception as defined by protocol during and for at least 6 months post study treatment\n\nExclusion Criteria:\n\n* Non-epithelial tumors\n* Ovarian tumors with low malignant potential (borderline tumors)\n* History of other malignancy of prognostic relevance within the last 5 years, except for carcinoma in situ of the cervix or basal cell carcinoma, or tumors with a negligible risk for metastasis or death, such as adequately controlled basal-cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or carcinoma in situ of the breast\n* Previous treatment with more than 2 chemotherapy regimens\n* Any prior radiotherapy to the pelvis or abdomen\n* History or evidence on physical/neurological examination of central nervous system disease unrelated to cancer (uncontrolled seizures), unless adequately treated with standard medical therapy\n* Pre-existing peripheral neuropathy \\>/= common toxicity criteria (CTC) grade 2 (applicable for paclitaxel cohort only)\n* Inadequate organ function\n* Uncontrolled hypertension or clinically significant cardiovascular disease\n* Current known infection with human immunodeficiency virus (HIV) or active infection with hepatitis B virus (HBV), or hepatitis C virus (HCV)\n* Current chronic daily treatment with corticosteroids (\\>/= 10 mg per day of methylprednisolone or equivalent), excluding inhaled steroids\n* History of receiving any investigational treatment within 28 days prior to first study drug administration\n* For Part 2 of the trial: prior enrollment into Part 1 of the trial\n* Concurrent participation in any therapeutic clinical trial","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Part 1: Percentage of Participants With Adverse Events (AEs)","description":"An AE can be any unfavorable and unintended sign (including an abnormality laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.5","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Part 2: Progression Free Survival (PFS) as Assessed by a Blinded Independent Review Committee (IRC) Including Malignant Bowel Obstruction (MBO)","description":"PFS (IRC-Assessed) was defined as the time from randomization into Part 2 of the trial until progressive disease (PD), MBO or death from any cause, whichever occurred first per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. PD could base on symptom deterioration or was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of one or more new lesions and/or the unequivocal progression of existing non-target lesions.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.27","spread":null},{"groupId":"OG001","value":"2.74","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1- Objective Response Rate (ORR)","description":"ORR was defined as the number of participants with best overall response (BOR) of complete response (CR) or partial response (PR) recorded from the start of treatment, until the end of treatment. BOR documented as confirmed CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\\<)10 millimeter (mm). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3","spread":null},{"groupId":"OG001","value":"25.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 2- Objective Response Rate (ORR)","description":"ORR was defined as the number of participants with BOR of CR or PR recorded from the start of treatment, until the end of treatment. BOR documented as confirmed CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\\<)10 millimeter (mm). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.8","spread":null},{"groupId":"OG001","value":"8.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1: PFS Assessed by the Investigator","description":"PFS as assessed by Investigator was defined as the time from first dose of pertuzumab or chemotherapy in Part 1 of the trial, until disease progression according to RECIST version 1.1, symptomatic deterioration or death from any cause, whichever occurs first. PD could base on symptom deterioration or was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of one or more new lesions and/or the unequivocal progression of existing non-target lesions. Participants were censored at the last tumor assessment. Participants who have no tumor assessments after baseline and who were still alive will be censored at 1 day.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.07","spread":null},{"groupId":"OG001","value":"4.24","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 2: Progression-free Survival (PFS) Assessed by the Investigator","description":"PFS (Investigator-assessed) is defined as the time from randomization, until disease progression according to RECIST v1.1 including death or MBO, whichever occurs first. Censoring is based on the last tumor assessment. If no tumor assessment post baseline, then censoring is at day 1. PD could base on symptom deterioration or was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of one or more new lesions and/or the unequivocal progression of existing non-target lesions.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.22","spread":null},{"groupId":"OG001","value":"3.94","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 2: European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QoL) Questionnaire (QLQ) of Core 30 (C30) Score","description":"EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \\[1 'very poor' to 7 'Excellent'\\]). Scores averaged, transformed to 0-100 scale; for functional scores, a higher score represents a better level of functioning. For symptom scores, a higher score represents a more severe level of symptoms. For the global health status scores, a higher score represents a better quality of life.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.1","spread":"22.77"},{"groupId":"OG001","value":"74.9","spread":"20.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.6","spread":"33.16"},{"groupId":"OG001","value":"69.4","spread":"32.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.5","spread":"24.03"},{"groupId":"OG001","value":"65.9","spread":"23.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.2","spread":"25.34"},{"groupId":"OG001","value":"84.9","spread":"20.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.7","spread":"30.01"},{"groupId":"OG001","value":"68.3","spread":"29.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.2","spread":"28.75"},{"groupId":"OG001","value":"38.4","spread":"27.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","spread":"15.68"},{"groupId":"OG001","value":"12.4","spread":"20.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.2","spread":"31.34"},{"groupId":"OG001","value":"31.1","spread":"29.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.5","spread":"28.47"},{"groupId":"OG001","value":"21.5","spread":"27.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.3","spread":"31.25"},{"groupId":"OG001","value":"31.5","spread":"31.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.9","spread":"30.19"},{"groupId":"OG001","value":"21.0","spread":"26.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.6","spread":"32.41"},{"groupId":"OG001","value":"26.4","spread":"32.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.5","spread":"26.49"},{"groupId":"OG001","value":"14.4","spread":"22.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.6","spread":"28.78"},{"groupId":"OG001","value":"13.4","spread":"22.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.1","spread":"24.99"},{"groupId":"OG001","value":"61.1","spread":"22.29"}]}]}]},{"type":"SECONDARY","title":"Part 2: Percentage of Participants With Adverse Events (AEs)","description":"An AE can be any unfavorable and unintended sign (including an abnormality laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 2: Overall Survival","description":"Overall survival was defined as the time from randomization into Part 2 of the trial until death from any cause","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.18","spread":null},{"groupId":"OG001","value":"8.36","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":22},"commonTop":["Diarrhoea","Nausea","Anaemia","Asthenia","Vomiting"]}}}